539 related articles for article (PubMed ID: 31185140)
21. Curcuminoids in neurodegenerative diseases.
Kim DS; Kim JY; Han Y
Recent Pat CNS Drug Discov; 2012 Dec; 7(3):184-204. PubMed ID: 22742420
[TBL] [Abstract][Full Text] [Related]
22. [Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities].
Klivényi P; Vécsei L
Orv Hetil; 1997 Feb; 138(6):331-5. PubMed ID: 9082290
[TBL] [Abstract][Full Text] [Related]
23. Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer's disease, Parkinson's disease and ischemic brain stroke: their molecular targets and action mechanisms.
Choi DY; Choi H
Arch Pharm Res; 2015 Feb; 38(2):139-70. PubMed ID: 25348867
[TBL] [Abstract][Full Text] [Related]
24. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
25. Endocannabinoid System in Neurological Disorders.
Ranieri R; Laezza C; Bifulco M; Marasco D; Malfitano AM
Recent Pat CNS Drug Discov; 2016; 10(2):90-112. PubMed ID: 27364363
[TBL] [Abstract][Full Text] [Related]
26. Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer's Disease: A Systematic Review.
da Costa IM; Freire MAM; de Paiva Cavalcanti JRL; de Araújo DP; Norrara B; Moreira Rosa IMM; de Azevedo EP; do Rego ACM; Filho IA; Guzen FP
Curr Neuropharmacol; 2019; 17(5):406-421. PubMed ID: 29338678
[TBL] [Abstract][Full Text] [Related]
27. Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases.
Chen D; Zhang T; Lee TH
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32784556
[TBL] [Abstract][Full Text] [Related]
28. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders.
Mattson MP
Ann N Y Acad Sci; 2004 Mar; 1012():37-50. PubMed ID: 15105254
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
[TBL] [Abstract][Full Text] [Related]
30. Flavonoid-based therapies in the early management of neurodegenerative diseases.
Solanki I; Parihar P; Mansuri ML; Parihar MS
Adv Nutr; 2015 Jan; 6(1):64-72. PubMed ID: 25593144
[TBL] [Abstract][Full Text] [Related]
31. Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders.
Yavarpour-Bali H; Ghasemi-Kasman M; Pirzadeh M
Int J Nanomedicine; 2019; 14():4449-4460. PubMed ID: 31417253
[TBL] [Abstract][Full Text] [Related]
32. Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders.
Ullah MF; Ahmad A; Bhat SH; Abu-Duhier FM; Barreto GE; Ashraf GM
Neurosci Biobehav Rev; 2019 Jul; 102():95-105. PubMed ID: 30959072
[TBL] [Abstract][Full Text] [Related]
33. Curcumin and Health.
Pulido-Moran M; Moreno-Fernandez J; Ramirez-Tortosa C; Ramirez-Tortosa M
Molecules; 2016 Feb; 21(3):264. PubMed ID: 26927041
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective properties of curcumin in toxin-base animal models of Parkinson's disease: a systematic experiment literatures review.
Wang XS; Zhang ZR; Zhang MM; Sun MX; Wang WW; Xie CL
BMC Complement Altern Med; 2017 Aug; 17(1):412. PubMed ID: 28818104
[TBL] [Abstract][Full Text] [Related]
35. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.
Vosler PS; Brennan CS; Chen J
Mol Neurobiol; 2008 Aug; 38(1):78-100. PubMed ID: 18686046
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotective properties of curcumin in Alzheimer's disease--merits and limitations.
Chin D; Huebbe P; Pallauf K; Rimbach G
Curr Med Chem; 2013; 20(32):3955-85. PubMed ID: 23931272
[TBL] [Abstract][Full Text] [Related]
37. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.
Choonara YE; Pillay V; Du Toit LC; Modi G; Naidoo D; Ndesendo VMK; Sibambo SR
Int J Mol Sci; 2009 Jun; 10(6):2510-2557. PubMed ID: 19582217
[TBL] [Abstract][Full Text] [Related]
38. Biological metals and metal-targeting compounds in major neurodegenerative diseases.
Barnham KJ; Bush AI
Chem Soc Rev; 2014 Oct; 43(19):6727-49. PubMed ID: 25099276
[TBL] [Abstract][Full Text] [Related]
39. The impact of curcumin and its modified formulations on Alzheimer's disease.
Farkhondeh T; Samarghandian S; Pourbagher-Shahri AM; Sedaghat M
J Cell Physiol; 2019 Aug; 234(10):16953-16965. PubMed ID: 30847942
[TBL] [Abstract][Full Text] [Related]
40. A new hypothesis of neurodegenerative diseases: the deleterious network hypothesis.
Ying W
Med Hypotheses; 1996 Oct; 47(4):307-13. PubMed ID: 8910880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
